Petros Pharmaceuticals (Petros Pharmaceuticals) Debt-to-Revenue : 1.44 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Petros Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.55 Mil. Petros Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.46 Mil. Petros Pharmaceuticals's annualized Revenue for the quarter that ended in Mar. 2024 was $5.56 Mil. Petros Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 1.44.

Petros Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Petros Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Debt-to-Revenue Chart

Petros Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

0.88

0.75

0.05

1.65

1.42

Petros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial													0.93	1.12	1.30	N/A	1.44

Competitive Comparison of Petros Pharmaceuticals's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Debt-to-Revenue falls into.

Petros Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Petros Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.282	+	6.995)	/	5.822
	=	1.42

Petros Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.554	+	6.46)	/	5.556
	=	1.44

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Petros Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.petrospharma.com

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley	director	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman	director, 10 percent owner
Jcp Iii Sm Aiv, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan	officer: Chief Financial Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor	officer: Pres. & Chief Comm. Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek	officer: President, Timm Medical	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold	officer: Prin. Acct. Off/Prin. Fin. Off	200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726